Latest company announcements, clinical milestones, and platform updates.
Medfiniti exhibited at the American College of Gastroenterology's 2026 Annual Scientific Meeting, held October 9–14, 2026, at the Music City Center in Nashville, Tennessee.
SourceNine centers performed their first HemWell MD procedures of 2026 in September, bringing the number of centers doing procedures to 67.
A BMC Gastroenterology meta-analysis of 76 reports, published September 19, 2026, estimated a pooled global hemorrhoid prevalence of 17%, and 21.5% when found by colonoscopy.
SourceSeptember 2026 set a new monthly record: 675 procedures, passing April's 650. 67 centers doing procedures.
HemWell MD centers performed 622 procedures in August 2026, with 58 centers doing procedures. Nine new centers started as the Gen 2 rollout expanded.
A five-year randomized trial in Diseases of the Colon & Rectum found excisional hemorrhoidectomy had the lowest symptom recurrence (24%); laser hemorrhoidoplasty was close (29%) with an easier recovery. HemWell MD's Hemwellectomy compares favorably: pooled clinical series show recurrence of roughly 0–10% (90–100% efficacy), with minimal pain and no extended recovery.
SourceA Frontiers in Medicine review, published August 18, 2026, found rectal artery embolization for bleeding hemorrhoids has high technical success but more variable long-term results.
SourceHemWell MD centers performed 608 procedures in July 2026 at 50 centers, including five that started procedures that month, as the Gen 2 rollout continued.
Medfiniti signed a Master Service Agreement with United Digestive — a premier GI practice management network with 81+ clinic locations and 129 specialized physicians across the Southeastern U.S. Additionally, the USPI rollout has begun and HCA has updated its Master Agreement for Gen 2 device deployment, advancing HemWell MD across major national healthcare networks.
USPI Coding News edition published with official CPT code guidance for the Hemwellectomy procedure. Medicare 2026 reimbursement rate established at $1,432.51 for CPT codes 46945 and 46946, standardizing payment across ASC networks nationwide.
HemWell MD centers performed 650 procedures in April 2026, the most in a single month at that time, bringing the year-to-date total to 2,101.
HemWell MD Gen 2 rollout continues across all 51 active clinical centers nationwide. Gen 1 replacement underway while maintaining seamless patient care continuity.
HemWell MD Gen 2 full launch: Gen 2 launched nationally in February 2026 after a Q4 2025 soft launch. The platform passes 40,000 procedures since the acquisition across 44 active clinical centers, establishing the foundation for continued platform expansion.
Gen 2 deployment supports expansion into additional states with new physician partnerships and center rollouts announced for Q1–Q2 2026.
Medfiniti began a soft launch of HemWell MD Gen 2 at select centers in Q4 2025, ahead of the full launch in February 2026.
Subscribe to receive the latest Medfiniti news and platform updates.